HRP20150961T1 - Uporaba amidoksimskih estera karboksilne kiseline i n-hidroksigvanidinskih estera karboksilne kiseline za proizvodnju prolijeka - Google Patents
Uporaba amidoksimskih estera karboksilne kiseline i n-hidroksigvanidinskih estera karboksilne kiseline za proizvodnju prolijeka Download PDFInfo
- Publication number
- HRP20150961T1 HRP20150961T1 HRP20150961TT HRP20150961T HRP20150961T1 HR P20150961 T1 HRP20150961 T1 HR P20150961T1 HR P20150961T T HRP20150961T T HR P20150961TT HR P20150961 T HRP20150961 T HR P20150961T HR P20150961 T1 HRP20150961 T1 HR P20150961T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- carboxylic acid
- acid esters
- amidoxime
- hydroxyguanidine
- Prior art date
Links
- -1 amidoxime carboxylic acid esters Chemical class 0.000 title claims 5
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000012907 medicinal substance Substances 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 201000002311 trypanosomiasis Diseases 0.000 claims 2
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 206010011668 Cutaneous leishmaniasis Diseases 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 108010091175 Matriptase Proteins 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- WFBHRSAKANVBKH-UHFFFAOYSA-N N-hydroxyguanidine Chemical group NC(=N)NO WFBHRSAKANVBKH-UHFFFAOYSA-N 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 241000233870 Pneumocystis Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims 1
- 150000001409 amidines Chemical class 0.000 claims 1
- 150000005840 aryl radicals Chemical class 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 claims 1
- 229950007095 diminazene Drugs 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims 1
- 229960004448 pentamidine Drugs 0.000 claims 1
- 201000000317 pneumocystosis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002911 sialidase inhibitor Substances 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/62—Oximes having oxygen atoms of oxyimino groups esterified
- C07C251/64—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids
- C07C251/66—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids with the esterifying carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (4)
1. Uporaba amidoksimskog estera karboksilne kiseline formule (I) ili N-hidroksigvanidinskog estera karboksilne kiseline formule (II)
[image]
gdje je n=0, ...., 12 i R1 je odabran iz grupe koja se sastoji od vodika, alkilnog radikala i arilnog radikala i njihovih soli, kao nadomjestak jedne ili više amidinskih, N-hidroksiamidinskih (amidoksimskih), gvanidinskih ili N-hidroksigvanidinskih funkcija ljekovite tvari u lijekovima, za poboljšanje topivosti i/ili bioraspoloživosti lijeka, kararakterizirana na način da je lijek odabran iz grupe inhibitora proteaza, gdje je inhibitor proteaza inhibitor trombina, inhibitor faktora Xa, faktora VII ili svih proteaza koagulacijske kaskade, ili inhibitor matriptaze, tvari koje se ugrađuju u DNA i RNA, inhibitora enzima virusa i antagonista receptora N-metil-D-aspartata.
2. Uporaba u skladu s patentnim zahtjevom 1, karakterizirana na način da je tvar koja se ugrađuje u DNA i RNA pentamidin, diminazen ili izometamid.
3. Uporaba u skladu s patentnim zahtjevom 1, karakterizirana na način da je inhibitor enzima virusa inhibitor neuraminidaze.
4. Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je ljekovita tvar konfigurirana za prevenciju i liječenje visceralne i/ili kutane Leischmanijaze, tripanosomijaze, druge faze tripanosomijaze ili pneumonije uzrokovane Pneumocystis carnii, za inhibiranje rasta malignih tumora, za sprječavanje zgrušavanja krvi, smanjenje krvnog tlaka, za zaštitu živaca ili za borbu protiv virusnih infekcija uključujući gripu i HIV.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008007381A DE102008007381A1 (de) | 2008-02-01 | 2008-02-01 | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
| EP09705303.7A EP2249821B1 (de) | 2008-02-01 | 2009-02-02 | Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs |
| PCT/EP2009/051132 WO2009095499A1 (de) | 2008-02-01 | 2009-02-02 | Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150961T1 true HRP20150961T1 (hr) | 2015-11-06 |
Family
ID=40532565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150961TT HRP20150961T1 (hr) | 2008-02-01 | 2015-09-11 | Uporaba amidoksimskih estera karboksilne kiseline i n-hidroksigvanidinskih estera karboksilne kiseline za proizvodnju prolijeka |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20110028756A1 (hr) |
| EP (3) | EP2732816A1 (hr) |
| JP (2) | JP2011510956A (hr) |
| KR (1) | KR20100110875A (hr) |
| CN (1) | CN101951897B (hr) |
| AU (1) | AU2009209560B2 (hr) |
| BR (1) | BRPI0906569A2 (hr) |
| CA (1) | CA2713784C (hr) |
| CY (1) | CY1116801T1 (hr) |
| DE (1) | DE102008007381A1 (hr) |
| DK (1) | DK2249821T3 (hr) |
| ES (1) | ES2547117T3 (hr) |
| HK (1) | HK1153144A1 (hr) |
| HR (1) | HRP20150961T1 (hr) |
| HU (1) | HUE026276T2 (hr) |
| IL (1) | IL207286A0 (hr) |
| PL (1) | PL2249821T3 (hr) |
| PT (1) | PT2249821E (hr) |
| SI (1) | SI2249821T1 (hr) |
| WO (1) | WO2009095499A1 (hr) |
| ZA (1) | ZA201004767B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9662308B2 (en) | 2008-02-01 | 2017-05-30 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Orally bioavailable pentamidine prodrugs for the treatment of diseases |
| DE102008007381A1 (de) | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
| DE102009004204A1 (de) * | 2009-01-09 | 2010-07-15 | Christian-Albrechts-Universität Zu Kiel | Verfahren zur verbesserten Bioaktivierung von Arzneistoffen |
| EP2550966B1 (de) * | 2011-07-25 | 2016-10-19 | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG | Dabigatran-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel |
| LT2550963T (lt) | 2011-07-25 | 2017-02-27 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Pentamidino-amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų naudojimas kaip vaistų |
| ES2416004B1 (es) * | 2012-01-24 | 2014-01-28 | Investigaciones Farmaceuticas Y Veterinarias, S.L. | Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales. |
| CN103420994B (zh) * | 2012-05-24 | 2016-04-06 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| US9375411B2 (en) * | 2012-12-21 | 2016-06-28 | Verlyx Pharma Inc. | Uses and methods for the treatment of liver diseases or conditions |
| CN106831611B (zh) * | 2017-01-23 | 2019-06-21 | 北京化工大学 | 一种偕胺肟类化合物及其在制备抑制癌细胞增殖药的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4321444A1 (de) * | 1993-06-28 | 1995-01-05 | Bernd Prof Dr Clement | Pharmazeutische Zubereitung |
| JP2001031586A (ja) * | 1999-07-14 | 2001-02-06 | Sunstar Inc | 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物 |
| EP1294405A2 (en) | 2000-06-14 | 2003-03-26 | Corixa Corporation | Prodrug compounds cleavable by thimet oligopeptidase |
| ES2364452T3 (es) * | 2001-06-11 | 2011-09-02 | Medarex, Inc. | Método para diseñar compuestos profármacos activados por cd10. |
| MXPA04003169A (es) * | 2001-10-03 | 2004-07-08 | Pharmacia Corp | Profarmacos de compuestos policiclicos sustituidos utiles para inhibicion selectiva de la cascada de coagulacion. |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| JPWO2005049636A1 (ja) * | 2003-11-21 | 2007-06-07 | 日本電気株式会社 | タンパク質の分析方法 |
| CA2572161C (en) | 2004-06-30 | 2012-10-02 | Toyama Chemical Co., Ltd. | Novel arylamidine derivative, salt thereof, and antifungal containing these |
| DE102006034256A1 (de) * | 2006-07-21 | 2008-01-31 | Christian-Albrechts-Universität Zu Kiel | Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln |
| DE102008007381A1 (de) | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
-
2008
- 2008-02-01 DE DE102008007381A patent/DE102008007381A1/de not_active Withdrawn
-
2009
- 2009-02-02 EP EP20140155230 patent/EP2732816A1/de not_active Ceased
- 2009-02-02 EP EP15178466.7A patent/EP2985021A1/de not_active Withdrawn
- 2009-02-02 JP JP2010544724A patent/JP2011510956A/ja not_active Withdrawn
- 2009-02-02 DK DK09705303.7T patent/DK2249821T3/en active
- 2009-02-02 EP EP09705303.7A patent/EP2249821B1/de active Active
- 2009-02-02 HU HUE09705303A patent/HUE026276T2/en unknown
- 2009-02-02 CN CN200980103401.7A patent/CN101951897B/zh not_active Expired - Fee Related
- 2009-02-02 ES ES09705303.7T patent/ES2547117T3/es active Active
- 2009-02-02 SI SI200931253T patent/SI2249821T1/sl unknown
- 2009-02-02 AU AU2009209560A patent/AU2009209560B2/en not_active Ceased
- 2009-02-02 WO PCT/EP2009/051132 patent/WO2009095499A1/de active Application Filing
- 2009-02-02 CA CA2713784A patent/CA2713784C/en active Active
- 2009-02-02 KR KR1020107018471A patent/KR20100110875A/ko not_active Application Discontinuation
- 2009-02-02 PT PT97053037T patent/PT2249821E/pt unknown
- 2009-02-02 PL PL09705303T patent/PL2249821T3/pl unknown
- 2009-02-02 BR BRPI0906569-5A patent/BRPI0906569A2/pt not_active IP Right Cessation
-
2010
- 2010-07-07 ZA ZA2010/04767A patent/ZA201004767B/en unknown
- 2010-07-29 IL IL207286A patent/IL207286A0/en unknown
- 2010-07-30 US US12/847,415 patent/US20110028756A1/en not_active Abandoned
-
2011
- 2011-07-15 HK HK11107361.3A patent/HK1153144A1/zh not_active IP Right Cessation
-
2014
- 2014-08-08 US US14/455,272 patent/US9353047B2/en active Active
-
2015
- 2015-09-11 HR HRP20150961TT patent/HRP20150961T1/hr unknown
- 2015-10-20 CY CY20151100936T patent/CY1116801T1/el unknown
-
2016
- 2016-06-14 JP JP2016117936A patent/JP2016193927A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2713784A1 (en) | 2009-08-06 |
| PT2249821E (pt) | 2015-10-13 |
| BRPI0906569A2 (pt) | 2015-07-07 |
| KR20100110875A (ko) | 2010-10-13 |
| DE102008007381A1 (de) | 2009-08-13 |
| US9353047B2 (en) | 2016-05-31 |
| WO2009095499A1 (de) | 2009-08-06 |
| AU2009209560A1 (en) | 2009-08-06 |
| SI2249821T1 (sl) | 2015-12-31 |
| CN101951897B (zh) | 2016-01-20 |
| US20140350293A1 (en) | 2014-11-27 |
| EP2249821B1 (de) | 2015-07-29 |
| EP2249821A1 (de) | 2010-11-17 |
| ZA201004767B (en) | 2011-04-28 |
| AU2009209560B2 (en) | 2013-10-31 |
| HK1153144A1 (zh) | 2012-03-23 |
| EP2732816A1 (de) | 2014-05-21 |
| DK2249821T3 (en) | 2015-10-05 |
| EP2985021A1 (de) | 2016-02-17 |
| CN101951897A (zh) | 2011-01-19 |
| IL207286A0 (en) | 2010-12-30 |
| US20110028756A1 (en) | 2011-02-03 |
| ES2547117T3 (es) | 2015-10-01 |
| JP2011510956A (ja) | 2011-04-07 |
| JP2016193927A (ja) | 2016-11-17 |
| PL2249821T3 (pl) | 2015-12-31 |
| HUE026276T2 (en) | 2016-06-28 |
| CY1116801T1 (el) | 2017-03-15 |
| CA2713784C (en) | 2016-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150961T1 (hr) | Uporaba amidoksimskih estera karboksilne kiseline i n-hidroksigvanidinskih estera karboksilne kiseline za proizvodnju prolijeka | |
| JP2011510956A5 (hr) | ||
| Hsieh et al. | Strategies of development of antiviral agents directed against influenza virus replication | |
| WO2014023691A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| Lagoja et al. | Anti‐influenza virus agents: Synthesis and mode of action | |
| Wen et al. | Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses | |
| BR112012010282A2 (pt) | derivados de ácido carboxílico cíclico substituído por acilamino e seu uso como farmacêuticos | |
| BRPI0618362A2 (pt) | sais farmacêuticos inovadores e polimorfos de um inibidor de fator xa | |
| CA2658434A1 (en) | Improvement of the bioavailability of active substances having an amidine function in medicaments | |
| ES2270532T3 (es) | Inhibidores de cisteina y serina proteasa a base de alfa-cetoamidas que contienen quinolina. | |
| EA201500266A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| US8952039B2 (en) | Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease | |
| NZ603935A (en) | Novel immunomodulator and anti inflammatory compounds | |
| MA32240B1 (fr) | Inhibiteurs de désacétylases b à base d'hydroxamate | |
| Liu et al. | Enhanced anti-influenza agents conjugated with anti-inflammatory activity | |
| Hsu et al. | Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses | |
| CA2852750A1 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| Liu et al. | Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir | |
| Xie et al. | Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors | |
| JP6198741B2 (ja) | インフルエンザを処置するための化合物 | |
| UA113201C2 (xx) | Фторзамісні (3r,4r,5s)-5-гуанідино-4-фторациламіно-3-(пентан-3-ілокси)циклогексен-1-карбонові кислоти, їх ефіри і спосіб застосування | |
| US10221152B2 (en) | Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus | |
| CN110724102B (zh) | 一种含四氢罂粟碱-3-羧酸甲酯的多酚类化合物及其制备方法和应用 | |
| Shi et al. | Design, synthesis and biological activity of novel chalcone derivatives as anti-influenza agents | |
| US20160207908A1 (en) | Broad spectrum antiviral and antiparasitic agents |